Roth Capital Issues Pessimistic Forecast for BRTX Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Stock analysts at Roth Capital reduced their FY2028 earnings estimates for BioRestorative Therapies in a research report issued on Thursday, November 14th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of $5.40 for the year, down from their previous forecast of $5.43. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.76) per share.

BioRestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.22. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%. The business had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.30 million.

Separately, Roth Mkm boosted their price objective on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th.

BioRestorative Therapies Trading Down 1.9 %

Shares of BioRestorative Therapies stock opened at $1.51 on Friday. The firm’s 50-day moving average is $1.63 and its 200 day moving average is $1.60. BioRestorative Therapies has a 1 year low of $1.03 and a 1 year high of $3.67.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.